# A Study to Assess the Safety and Efficacy of Oral LPCN 1154A in Women With Severe PPD

> **NCT06979544** · PHASE3 · COMPLETED · sponsor: **Lipocine Inc.** · enrollment: 90 (actual)

## Conditions studied

- Depression, Postpartum
- Depression, Post-Partum
- Postpartum Depression (PPD)
- Post-Natal Depression
- Peripartum Depression
- Postnatal Depression

## Interventions

- **DRUG:** LPCN 1154A
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06979544
- **Lead sponsor:** Lipocine Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-06-16
- **Primary completion:** 2026-01-16
- **Final completion:** 2026-02-17
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2026-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06979544

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06979544, "A Study to Assess the Safety and Efficacy of Oral LPCN 1154A in Women With Severe PPD". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT06979544. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*